Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Dengue Fever Pipeline Drugs Market Report Overview

Dengue is a mosquito borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from nose, gums, or under skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy and healthy life style.

The dengue fever pipeline drugs market research report provides comprehensive information on the dengue fever targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also reviews key players involved in dengue fever targeted therapeutics development with respective active and dormant or discontinued projects.

Dengue Fever Pipeline Drugs Market Segmentation by Target

The key targets in the dengue fever pipeline drugs market are Envelope Protein, Nonstructural Protein 4B, Nonstructural Protein 5, Nonstructural Protein 1, Nonstructural Protein 3, and Premembrane Protein among others. Envelope Protein, Nonstructural Protein 4B, and Nonstructural Protein 5 have the highest number of dengue fever drugs in development in 2022.

Dengue Fever Pipeline Drugs Market Analysis, by Target

For more target insights on dengue fever pipeline drugs market, download a free report sample

Dengue Fever Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action of the dengue fever pipeline drugs market are Nonstructural Protein 4B Inhibitor, Nonstructural Protein 5 Inhibitor, Envelope Protein Inhibitor, Nonstructural Protein 3 Inhibitor, Toll Like Receptor 4 Antagonist, and Aryl Hydrocarbon Receptor Antagonist among others. Nonstructural Protein 4B Inhibitor and Nonstructural Protein 5 Inhibitor led the dengue fever pipeline drugs market in 2022.

Dengue Fever Pipeline Drugs Market Analysis, by Mechanisms of Action

For more MoA insights on the dengue fever pipeline drugs market, download a free report sample

Dengue Fever Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the dengue fever pipeline drugs market are subcutaneous, oral, intramuscular, intravenous, intradermal, nasal, parenteral, and transdermal. Subcutaneous is the most preferred RoA in the dengue fever pipeline drugs market.

Dengue Fever Pipeline Drugs Market Analysis, by Routes of Administration

For more RoA insights dengue fever pipeline drugs market, download a free report sample

Dengue Fever Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the dengue fever pipeline drugs market are small molecule, live attenuated vaccine, subunit vaccine, monoclonal antibody, vaccine, and recombinant vector vaccine among others. Small molecule leads the dengue fever pipeline drugs market in this segment.

Dengue Fever Pipeline Drugs Market Analysis, by Molecule Types

To know more about the molecule types in the dengue fever pipeline drugs market, download a free report sample

Dengue Fever Pipeline Drugs Market - Competitive Landscape

The leading companies in the dengue fever pipeline drugs market are Takeda Pharmaceutical Co Ltd, BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, 60 Degrees Pharmaceuticals LLC, and Abivax SA among others. Takeda Pharmaceutical Co Ltd has the highest number of dengue fever drugs in development in 2022.

Dengue Fever Pipeline Drugs Market Analysis, by Companies

To know more about the leading dengue fever pipeline drugs market players, download a free report sample

Dengue Fever Pipeline Drugs Market Overview

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Dengue Fever (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Dengue Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Dengue Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Dengue Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Dengue Fever (Infectious Disease)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Dengue Fever (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Dengue Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.